Results 231 to 240 of about 137,029 (384)

Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease

Alimentary Pharmacology and Therapeutics, 2017
A. Yarur, Vikram S. Kanagala, D. Stein, Frank Czul, M. Quintero, D. Agrawal, Amir C. Patel, Kari Best, C. Fox, K. Idstein, M. Abreu   +10 more
semanticscholar   +1 more source

Clinical Utility and Cost‐Effectiveness of Pretreatment NUDT15 Pharmacogenetic Testing to Prevent Thiopurine‐Induced Myelosuppression: A Genotype‐First Reverse Phenotyping Cohort Study Within the UK NIHR Inflammatory Bowel Disease Bioresource

Alimentary Pharmacology &Therapeutics, EarlyView.
Carriage of any loss of function NUDT15 varaint is associated with an increased risk of thiopurine‐induced myelosuppression. Pre‐treatment genotype testing of NUDT15. ABSTRACT Background The clinical utility and cost‐effectiveness of pre‐thiopurine NUDT15 pharmacogenetic testing in European and admixed populations are unknown.
Christopher Roberts, Jaime Peters, Aleksejs Sazonvos, Neil Goodman, Mohmmed Sharip, Rebecca Smith, Maria Bishara, Claire Bewshea, Simeng Lin, Neil Chanchlani, Phoebe Hodges, Fakhirah Badrulhisham, Aamir Saifuddin, Sean Carlson, Andrea Centritto, Alexandra Marley, Muhammad Saad, Karishma Sethi‐Aora, Laura White, Alaa Abdelmeguid, Laetitia Pele, Shaji Sebastian, Christian Selinger, Peter Irving, Laura Fachal, Gareth Walker, Rachel Palmer, Nick Kennedy, Jayne Houghton, Chris Hyde, Miles Parkes, James Goodhand, Tariq Ahmad   +32 more
wiley   +1 more source

Comparison of endoscopic healing and durability between combination therapy with infliximab and azathioprine versus infliximab monotherapy in pediatric Crohn's disease. [PDF]

Sci Rep
Kim YZ, Kim ES, Kwon Y, Kim SY, Kim H, Choe YH, Kim MJ.   +6 more
europepmc   +1 more source

Twenty‐Year Trends in Colectomy Rates and Advanced Therapy Prescribing in Lothian, Scotland

Alimentary Pharmacology &Therapeutics, EarlyView.
Prescribing of first‐line advanced therapy increased from 0 in 2004 to 115 in 2023, and absolute colectomy numbers decreased from 42 in 2004 to 7 in 2023. Piecewise linear regression found a join point in 2013 for both increased advanced therapy prescribing and decreased colectomy rates. ABSTRACT Background The impact of advanced therapy prescribing on
Alexander T. Elford, Nathan Constantine‐Cooke, Phil W. Jenkinson, Beatriz Gros, Nikolas Plevris, Mathew Lyons, Solomon Ong, Neil Greenlees, Victor Velasco‐Pardo, Claire O'Hare, Nicholas T. Ventham, Paul Henderson, David C. Wilson, Shahida Din, Colin L. Noble, Gareth‐Rhys Jones, Ian Arnott, Charlie W. Lees   +17 more
wiley   +1 more source

A Rare Complication of Infliximab [PDF]

Gastroenterology, 2018
Linda S. Yang, Damian Dowling
openaire   +2 more sources

Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis.

Clinical Gastroenterology and Hepatology, 2019
J. Colombel, O. Adedokun, C. Gasink, Long-Long Gao, F. Cornillie, G. D'Haens, P. Rutgeerts, W. Reinisch, W. Sandborn, S. Hanauer   +9 more
semanticscholar   +1 more source

Prescribing Inflammatory Bowel Disease Medications in Chronic Kidney Disease: A Practical Guide

Alimentary Pharmacology &Therapeutics, EarlyView.
Most therapies used in inflammatory bowel disease appear safe and effective when used in chronic kidney disease including on renal replacement therapy, particularly biologic therapies. Some caution should be considered when using conventional therapies and JAK inhibitors.
Lynna Chen, Ashish Srinivasan, Suet‐Wan Choy, Jeffrey Van, Habeeb Habeeb, Andrew Nguyen, Abhinav Vasudevan   +6 more
wiley   +1 more source

Meta‐Analysis: Intravenous Versus Subcutaneous Infliximab in Inflammatory Bowel Disease

Alimentary Pharmacology &Therapeutics, EarlyView.
There is uncertainty about the relative efficacy of subcutaneous (SC) compared to intravenous (IV) infliximab in inflammatory bowel disease (IBD). In this network meta‐analysis, SC infliximab was associated with high efficacy rates in IBD use, with a suggestion of clinical benefit above the IV formulation.
John David Chetwood, Arteen Arzivian, Yvonne Tran, Sudarshan Paramsothy, Rupert W. Leong   +4 more
wiley   +1 more source

PAO8: THE COST-EFFECTIVENESS OF INFLIXIMAB FOR SEVERE RHEUMATOID ARTHRITIS

, 2001
María Antonietta Barbieri, JB Wong, MF Drummond   +2 more
openalex   +1 more source

Granulocyte and Monocyte Adsorptive Apheresis Maintenance Therapy Restored the Loss of Response to Anti-TNF-Alpha Agents in the Patients With UC: A Case Report. [PDF]

J Clin Apher
Ueno N, Kobayashi Y, Sakatani A, Dokoshi T, Takahashi K, Ando K, Kashima S, Moriichi K, Tanabe H, Kamikokura Y, Tanino M, Fujiya M.   +11 more
europepmc   +1 more source